Published in J Virol on October 01, 1993
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature (2003) 10.76
HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology (2008) 3.72
Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J Virol (2006) 3.27
The human immunodeficiency virus type 1 Vif protein modulates the postpenetration stability of viral nucleoprotein complexes. J Virol (1996) 3.22
Highly purified human immunodeficiency virus type 1 reveals a virtual absence of Vif in virions. J Virol (1999) 2.66
Role of matrix in an early postentry step in the human immunodeficiency virus type 1 life cycle. J Virol (1998) 2.62
APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog (2008) 2.60
Biochemical activities of highly purified, catalytically active human APOBEC3G: correlation with antiviral effect. J Virol (2006) 2.58
Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Res (2007) 2.49
Human immunodeficiency virus type 1 Vif- mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity. J Virol (1995) 2.45
Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Rev Mol Med (2010) 2.43
Host restriction factors blocking retroviral replication. Annu Rev Genet (2008) 2.41
APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci (2009) 2.40
The Vif and Gag proteins of human immunodeficiency virus type 1 colocalize in infected human T cells. J Virol (1997) 2.39
Subcellular localization of the Vif protein of human immunodeficiency virus type 1. J Virol (1994) 2.35
Complementation of vif-defective human immunodeficiency virus type 1 by primate, but not nonprimate, lentivirus vif genes. J Virol (1995) 2.35
Role of Vif in human immunodeficiency virus type 1 reverse transcription. J Virol (1996) 2.35
Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. J Virol (2004) 2.34
Cytoskeleton association and virion incorporation of the human immunodeficiency virus type 1 Vif protein. J Virol (1996) 2.30
Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G. J Virol (2004) 2.27
The Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures. J Virol (1995) 2.25
The DNA deaminase activity of human APOBEC3G is required for Ty1, MusD, and human immunodeficiency virus type 1 restriction. J Virol (2008) 2.21
Peripheral blood mononuclear cells produce normal amounts of defective Vif- human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps. J Virol (1995) 2.19
Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA. J Virol (2001) 2.16
Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex. J Virol (1999) 2.16
Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process. J Virol (2000) 2.11
Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription. J Virol (2000) 2.00
Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytes. J Virol (1995) 1.97
Replication and pathogenicity of human immunodeficiency virus type 1 accessory gene mutants in SCID-hu mice. J Virol (1996) 1.80
Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. J Virol (1996) 1.76
Human immunodeficiency virus type 1 replication is modulated by host cyclophilin A expression levels. J Virol (1998) 1.73
Resistance of human T cell leukemia virus type 1 to APOBEC3G restriction is mediated by elements in nucleocapsid. Proc Natl Acad Sci U S A (2007) 1.73
Characterization of human immunodeficiency virus type 1 Vif particle incorporation. J Virol (1996) 1.69
Partial rescue of the Vif-negative phenotype of mutant human immunodeficiency virus type 1 strains from nonpermissive cells by intravirion reverse transcription. J Virol (2000) 1.60
Human immunodeficiency virus type 1 Vif protein binds to the Pr55Gag precursor. J Virol (1997) 1.55
Human immunodeficiency virus type 1 Vif is efficiently packaged into virions during productive but not chronic infection. J Virol (2003) 1.49
Mutational analysis of the HIV-1 auxiliary protein Vif identifies independent domains important for the physical and functional interaction with HIV-1 reverse transcriptase. Nucleic Acids Res (2009) 1.48
Molecular biology of the human immunodeficiency virus accessory proteins. J Virol (1994) 1.44
Vif and the p55(Gag) polyprotein of human immunodeficiency virus type 1 are present in colocalizing membrane-free cytoplasmic complexes. J Virol (1999) 1.44
Cysteine residues in the Vif protein of human immunodeficiency virus type 1 are essential for viral infectivity. J Virol (1994) 1.42
Comprehensive investigation of the molecular defect in vif-deficient human immunodeficiency virus type 1 virions. J Virol (2003) 1.41
Phenotypically Vif- human immunodeficiency virus type 1 is produced by chronically infected restrictive cells. J Virol (1997) 1.38
Biological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains. J Virol (1995) 1.36
Role of Vif in stability of the human immunodeficiency virus type 1 core. J Virol (2000) 1.34
The multimerization of human immunodeficiency virus type I Vif protein: a requirement for Vif function in the viral life cycle. J Biol Chem (2000) 1.32
Addition of deoxynucleosides enhances human immunodeficiency virus type 1 integration and 2LTR formation in resting CD4+ T cells. J Virol (2007) 1.31
Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. Curr HIV Res (2004) 1.26
Molecular biology and pathogenesis of animal lentivirus infections. Clin Microbiol Rev (1996) 1.26
vif-negative human immunodeficiency virus type 1 persistently replicates in primary macrophages, producing attenuated progeny virus. J Virol (1996) 1.22
Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. J Biol Chem (2002) 1.17
Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES. J Virol (2001) 1.12
Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors. Microbiol Mol Biol Rev (2009) 1.12
Comparative analyses of human immunodeficiency virus type 1 (HIV-1) and HIV-2 Vif mutants. J Virol (1995) 1.11
Interference to human immunodeficiency virus type 1 infection in the absence of downmodulation of the principal virus receptor, CD4. J Virol (1996) 1.10
Vif is a RNA chaperone that could temporally regulate RNA dimerization and the early steps of HIV-1 reverse transcription. Nucleic Acids Res (2007) 1.07
Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by a two-amino-acid insertion in HIV-1 Vif from a nonprogressing mother and child. J Virol (2002) 1.06
Conservation of an intact human immunodeficiency virus type 1 vif gene in vitro and in vivo. J Virol (1995) 1.06
APOBEC3G restricts early HIV-1 replication in the cytoplasm of target cells. Virology (2008) 1.04
Mass spectrometry analysis of HIV-1 Vif reveals an increase in ordered structure upon oligomerization in regions necessary for viral infectivity. Proteins (2007) 1.04
Implication of the lymphocyte-specific nuclear body protein Sp140 in an innate response to human immunodeficiency virus type 1. J Virol (2002) 1.03
HIV-1 Vif versus the APOBEC3 cytidine deaminases: an intracellular duel between pathogen and host restriction factors. Mol Aspects Med (2010) 1.03
Advances in the structural understanding of Vif proteins. Curr HIV Res (2008) 1.03
APOBEC3G: an intracellular centurion. Philos Trans R Soc Lond B Biol Sci (2009) 1.02
Antiviral Mechanism and Biochemical Basis of the Human APOBEC3 Family. Front Microbiol (2012) 1.00
Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro. J Virol (1997) 0.94
Functional domains of Tat required for efficient human immunodeficiency virus type 1 reverse transcription. J Virol (1999) 0.94
Differential virus restriction patterns of rhesus macaque and human APOBEC3A: implications for lentivirus evolution. Virology (2011) 0.92
Feline immunodeficiency virus Vif localizes to the nucleus. J Virol (2000) 0.90
Functional analysis of Vif protein shows less restriction of human immunodeficiency virus type 2 by APOBEC3G. J Virol (2005) 0.89
Inhibitors of human immunodeficiency virus type 1 reverse transcriptase target distinct phases of early reverse transcription. J Virol (2001) 0.89
Conservation of an intact vif gene of human immunodeficiency virus type 1 during maternal-fetal transmission. J Virol (1998) 0.86
Ring finger protein ZIN interacts with human immunodeficiency virus type 1 Vif. J Virol (2004) 0.86
HIV-1 Vif promotes the G₁- to S-phase cell-cycle transition. Blood (2010) 0.84
Vif is largely absent from human immunodeficiency virus type 1 mature virions and associates mainly with viral particles containing unprocessed gag. J Virol (2001) 0.83
Multi-scale modeling of HIV infection in vitro and APOBEC3G-based anti-retroviral therapy. PLoS Comput Biol (2012) 0.80
APOBEC3G-Augmented Stem Cell Therapy to Modulate HIV Replication: A Computational Study. PLoS One (2013) 0.79
The role of BST2/tetherin in feline retrovirus infection. Vet Immunol Immunopathol (2011) 0.77
Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science (1984) 33.32
DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells. Science (1988) 13.46
Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science (1985) 10.71
Temporal aspects of DNA and RNA synthesis during human immunodeficiency virus infection: evidence for differential gene expression. J Virol (1989) 9.37
Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemic T cells. Nature (1981) 9.25
The HIV 'A' (sor) gene product is essential for virus infectivity. Nature (1987) 7.51
Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA (1991) 6.83
The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science (1987) 6.16
Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J Immunol (1989) 6.02
Role of vif in replication of human immunodeficiency virus type 1 in CD4+ T lymphocytes. J Virol (1992) 5.85
Partial reverse transcripts in virions from human immunodeficiency and murine leukemia viruses. J Virol (1992) 4.72
Restricted expression of human T-cell leukemia--lymphoma virus (HTLV) in transformed human umbilical cord blood lymphocytes. Virology (1983) 4.11
Replicative and cytopathic potential of HTLV-III/LAV with sor gene deletions. Science (1986) 4.04
Viral DNA carried by human immunodeficiency virus type 1 virions. J Virol (1992) 3.93
A new HTLV-III/LAV protein encoded by a gene found in cytopathic retroviruses. Science (1986) 3.20
Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles. J Virol (1993) 3.01
Kinetics of expression of multiply spliced RNA in early human immunodeficiency virus type 1 infection of lymphocytes and monocytes. Proc Natl Acad Sci U S A (1991) 2.81
Rev activates expression of the human immunodeficiency virus type 1 vif and vpr gene products. J Virol (1991) 2.62
Expression of human immunodeficiency virus type 1 vif and vpr mRNAs is Rev-dependent and regulated by splicing. Virology (1991) 2.43
Conservation of amino-acid sequence motifs in lentivirus Vif proteins. Virus Genes (1992) 2.40
Identification of HTLV-III/LAV sor gene product and detection of antibodies in human sera. Science (1986) 2.35
Differences in cytopathogenicity and host cell range among infectious molecular clones of human immunodeficiency virus type 1 simultaneously isolated from an individual. J Virol (1988) 2.24
Cell-free transmission of Vif mutants of HIV-1. Virology (1992) 2.13
Reinfection results in accumulation of unintegrated viral DNA in cytopathic and persistent human immunodeficiency virus type 1 infection of CEM cells. J Exp Med (1990) 2.13
Biological characterization of human immunodeficiency virus type 1 and type 2 mutants in human peripheral blood mononuclear cells. Arch Virol (1992) 1.81
Accumulation of human immunodeficiency virus type 1 DNA in T cells: results of multiple infection events. J Virol (1990) 1.78
Recombinational analysis of a natural noncytopathic human immunodeficiency virus type 1 (HIV-1) isolate: role of the vif gene in HIV-1 infection kinetics and cytopathicity. J Virol (1991) 1.73
Identification of a feline immunodeficiency virus gene which is essential for cell-free virus infectivity. J Virol (1992) 1.59
Interaction of a noncytopathic human immunodeficiency virus type 1 (HIV-1) with target cells: efficient virus entry followed by delayed expression of its RNA and protein. Virology (1990) 1.33
Cells surviving infection by human immunodeficiency virus type 1: vif or vpu mutants produce non-infectious or markedly less cytopathic viruses. J Gen Virol (1992) 1.22
Development of techniques to analyse the formation of HIV provirus in primary human macrophages. Res Virol (1991) 1.19
Titration of human immunodeficiency virus type 1 (HIV-1) and quantitative analysis of virus expression in vitro using liquid RNA-RNA hybridization. J Virol Methods (1990) 1.17
Human immunodeficiency virus type 1 vif, vpr, and vpu mutants can produce persistently infected cells. Arch Virol (1991) 1.01
3'-orf and sor genes of human immunodeficiency virus: in vitro transcription-translation and immunoreactive domains. Proc Natl Acad Sci U S A (1987) 0.99
Kinetics of early HIV-1 gene expression in infected H9 cells assessed by PCR. Oncogene (1991) 0.95
Prevalence of antibodies to recombinant virion infectivity factor in the sera of prospectively studied patients with HIV-1 infection. J Med Virol (1992) 0.82
Cytokines and arachidonic metabolites produced during human immunodeficiency virus (HIV)-infected macrophage-astroglia interactions: implications for the neuropathogenesis of HIV disease. J Exp Med (1992) 2.48
Gene expression profiling reveals the profound upregulation of hypoxia-responsive genes in primary human astrocytes. Physiol Genomics (2006) 2.38
Differences in cytopathogenicity and host cell range among infectious molecular clones of human immunodeficiency virus type 1 simultaneously isolated from an individual. J Virol (1988) 2.24
Detection of HIV-1 DNA in microglia/macrophages, astrocytes and neurons isolated from brain tissue with HIV-1 encephalitis by laser capture microdissection. Brain Pathol (2003) 2.11
Aberrant Gag protein composition of a human immunodeficiency virus type 1 vif mutant produced in primary lymphocytes. J Virol (1995) 1.97
Downregulation of cell surface molecules during noncytopathic infection of T cells with human immunodeficiency virus. J Virol (1987) 1.85
Persistent productive infection of human glial cells by human immunodeficiency virus (HIV) and by infectious molecular clones of HIV. J Virol (1987) 1.84
Recombinational analysis of a natural noncytopathic human immunodeficiency virus type 1 (HIV-1) isolate: role of the vif gene in HIV-1 infection kinetics and cytopathicity. J Virol (1991) 1.73
Human immunodeficiency virus type 1 DNA synthesis, integration, and efficient viral replication in growth-arrested T cells. J Virol (1993) 1.57
Inhibition of HIV replication in acute and chronic infections in vitro by a Tat antagonist. Science (1991) 1.55
Cysteine residues in the Vif protein of human immunodeficiency virus type 1 are essential for viral infectivity. J Virol (1994) 1.42
Transfer of Epstein-Barr virus receptors to receptor-negative cells permits virus penetration and antigen expression. Proc Natl Acad Sci U S A (1980) 1.38
Interaction of a noncytopathic human immunodeficiency virus type 1 (HIV-1) with target cells: efficient virus entry followed by delayed expression of its RNA and protein. Virology (1990) 1.33
Highly productive infection with pseudotyped human immunodeficiency virus type 1 (HIV-1) indicates no intracellular restrictions to HIV-1 replication in primary human astrocytes. J Virol (2001) 1.28
Transfection of DNA into adherent cells by DEAE-dextran/DMSO method increases drastically if the cells are removed from surface and treated in suspension. Nucleic Acids Res (1989) 1.27
A human T-cell line resistant to cytopathic effects of the human immunodeficiency virus (HIV). Virology (1987) 1.26
An efficient method for reassembly of fusogenic Sendai virus envelopes after solubilization of intact virions with Triton X-100. FEBS Lett (1978) 1.25
Quantitative measurement of fusion between human immunodeficiency virus and cultured cells using membrane fluorescence dequenching. FEBS Lett (1988) 1.24
vif-negative human immunodeficiency virus type 1 persistently replicates in primary macrophages, producing attenuated progeny virus. J Virol (1996) 1.22
Susceptibility of human glial cells to infection with human immunodeficiency virus (HIV). FEBS Lett (1987) 1.19
Infection of macrophages with lymphotropic human immunodeficiency virus type 1 can be arrested after viral DNA synthesis. J Virol (1993) 1.19
Differences in the basal activity of the long terminal repeat determine different replicative capacities of two closely related human immunodeficiency virus type 1 isolates. J Virol (1990) 1.19
Role of Ca++ in virus-induced membrane fusion. Ca++ accumulation and ultrastructural changes induced by Sendai virus in chicken erythrocytes. J Cell Biol (1978) 1.10
Activated v-myc and v-ras oncogenes do not transform normal human lymphocytes. Mol Cell Biol (1986) 1.07
Conservation of an intact human immunodeficiency virus type 1 vif gene in vitro and in vivo. J Virol (1995) 1.06
Immortalization of human T lymphocytes after transfection of Epstein-Barr virus DNA. Science (1986) 1.04
Induction of rapid and extensive beta-chemokine synthesis in macrophages by human immunodeficiency virus type 1 and gp120, independently of their coreceptor phenotype. J Virol (2001) 1.02
Implantation of the isolated human erythrocyte anion channel into plasma membranes of Friend erythroleukemic cells by use of Sendai virus envelopes. Proc Natl Acad Sci U S A (1979) 1.02
Antibodies to HTLV-III/LAV in Venezuelan patients with acute malarial infections. N Engl J Med (1986) 1.01
Expression of Epstein-Barr virus (EBV) DNA and cloned DNA fragments in human lymphocytes following Sendai virus envelope-mediated gene transfer. Proc Natl Acad Sci U S A (1984) 1.01
Alteration of lymphocyte surface properties by insertion of foreign functional components of plasma membrane. Proc Natl Acad Sci U S A (1980) 1.00
Necrotizing lymphoid vasculitis in X-linked lymphoproliferative syndrome. Arch Pathol Lab Med (1985) 0.99
Establishment of retrovirus-, Epstein-Barr virus-positive B-lymphoblastoid cell lines derived from individuals at risk for acquired immune deficiency syndrome (AIDS). AIDS Res (1986) 0.99
Virus-cell membrane fusion does not predict efficient infection of alveolar macrophages by human immunodeficiency virus type 1 (HIV-1). Virology (1992) 0.98
Discovery and characterization of an HIV-1 Tat antagonist. Biochem Soc Trans (1992) 0.97
Testing for antibodies to AIDS-associated retrovirus (HTLV-III/LAV) by indirect fixed cell immunofluorescence: specificity, sensitivity, and applications. J Med Virol (1986) 0.97
Infection of normal human epithelial cells by Epstein-Barr virus. Science (1983) 0.96
Regulated expression of human immunodeficiency virus type 1 in human glial cells: induction of dormant virus. Pathobiology (1992) 0.94
Restoration of cell surface CD4 expression in human immunodeficiency virus type 1-infected cells by treatment with a Tat antagonist. J Virol (1992) 0.94
Induction of dormant HIV-1 by sodium butyrate: involvement of the TATA box in the activation of the HIV-1 promoter. AIDS (1991) 0.94
Retroviral etiology of the acquired immune deficiency syndrome (AIDS). AIDS Res (1986) 0.94
Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro. J Virol (1997) 0.94
The redox state of cysteines in human immunodeficiency virus type 1 Vif in infected cells and in virions. Biochem Biophys Res Commun (1997) 0.93
Replication of different clones of human immunodeficiency virus type 1 in primary fetal human astrocytes: enhancement of viral gene expression by Nef. J Neurovirol (1999) 0.93
Contribution of multiple rounds of viral entry and reverse transcription to expression of human immunodeficiency virus type 1. A quantitative kinetic study. J Biol Chem (1991) 0.92
Production of infectious Epstein--Barr virus in mouse lymphocytes. Nature (1981) 0.91
Expression of the T4 molecule (AIDS virus receptor) by human brain-derived cells. FEBS Lett (1987) 0.90
A system for the high efficiency replication of HIV-1 in neural cells and its application to anti-viral evaluation. Virology (1992) 0.89
Prevalence of AIDS-associated retrovirus and antibodies among male homosexuals at risk for AIDS in Greenwich Village. AIDS Res (1986) 0.88
Redefinition of tropism of common macrophage-tropic human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (1995) 0.88
Full-length CD4 electroinserted in the erythrocyte membrane as a long-lived inhibitor of infection by human immunodeficiency virus. Proc Natl Acad Sci U S A (1991) 0.87
The establishment of rodent cell lines persistently producing HIV-1. Virology (1992) 0.87
The detection of Epstein-Barr virus receptors utilizing radiolabelled virus. J Gen Virol (1981) 0.86
Generation of CD4+ and CD8+ T-cell clones from PBLs of HIV-1 infected subjects using herpesvirus saimiri. Nat Med (1996) 0.86
Cloning of differentially expressed genes in an HIV-1 resistant T cell clone by rapid subtraction hybridization, RaSH. Gene (2001) 0.86
Uniform detection of HIV-1 in alveolar macrophages of pediatric but not adult AIDS patients. J Leukoc Biol (1993) 0.86
Epstein-Barr virus co-reconstituted with Sendai virus envelopes infects Epstein-Barr virus-receptor negative cells. Biochim Biophys Acta (1981) 0.85
Infection of mouse lymphocytes by Epstein-Barr virus. II. Stimulation of cellular DNA synthesis by EBV in the absence of EBNA induction and cell transformation. Virology (1984) 0.84
Induction of Epstein-Barr virus in B-lymphoblastoid cells by human immunodeficiency virus type 1. Int J Cancer (1989) 0.84
Vif is largely absent from human immunodeficiency virus type 1 mature virions and associates mainly with viral particles containing unprocessed gag. J Virol (2001) 0.83
Peptide inhibitors of HIV-1 protease and viral infection of peripheral blood lymphocytes based on HIV-1 Vif. Proc Natl Acad Sci U S A (1998) 0.83
Prolonged infection of peripheral blood lymphocytes by Vif-negative HIV type 1 induces resistance to productive HIV type 1 infection through soluble factors. AIDS Res Hum Retroviruses (2000) 0.83
Epstein-Barr virus and chronic lymphadenomegaly in male homosexuals with acquired immunodeficiency syndrome (AIDS). AIDS Res (1986) 0.82
A mechanism of restricted human immunodeficiency virus type 1 expression in human glial cells. J Virol (1996) 0.82
Isolation and long-term culture of primary ocular human immunodeficiency virus type 1 isolates in primary astrocytes. J Neurovirol (1997) 0.82
Low-cytopathic infectious clone of human immunodeficiency virus type I (HIV-I). FEBS Lett (1988) 0.81
Role of Epstein-Barr virus in acquired immune deficiency syndrome. Adv Exp Med Biol (1985) 0.81
Non-Hodgkin's lymphoma after treatment of Hodgkin's disease: association with Epstein-Barr virus. Ann Intern Med (1986) 0.80
Genetic variability and function of the long terminal repeat from syncytium-inducing and non-syncytium-inducing human immunodeficiency virus type 1. AIDS Res Hum Retroviruses (1996) 0.80
Improvement of Herpesvirus saimiri T cell immortalization procedure to generate multiple CD4+ T-cell clones from peripheral blood lymphocytes of AIDS patients. J Immunol Methods (1997) 0.80
Dependence of CD8+ T-cell-mediated suppression of HIV type 1 on viral phenotypes and mediation of phenotype-dependent suppression by viral envelope gene and not by beta-chemokines. AIDS Res Hum Retroviruses (2000) 0.80
Expression of glial fibrillary acidic protein in human glioma cell lines as detected by molecular hybridization. Acta Neuropathol (1987) 0.80
Membranes of EBV-carrying virus nonproducer cells inhibit leukocyte migration of EBV-seropositive but not seronegative donors. J Immunol (1981) 0.80
Primary brain lymphoma in the immunocompetent host: relation to Epstein-Barr virus. Mod Pathol (1990) 0.80
Transfer of the Epstein-Barr virus (EBV) DNA fragment coding for EBNA-1, the putative transforming antigen of EBV, into normal human lymphocytes: gene expression without cell transformation. Biochem Biophys Res Commun (1986) 0.80
Establishment of human glial cell lines chronically infected with the human immunodeficiency virus. Virology (1988) 0.80
Are beta-chemokines innocent bystanders in HIV type 1 disease progression? AIDS Res Hum Retroviruses (1998) 0.79
Human immunodeficiency virus type 1 can infect human retinal pigment epithelial cells in culture and alter the ability of the cells to phagocytose rod outer segment membranes. AIDS Res Hum Retroviruses (2000) 0.79
Lateral mobility of beta-receptors involved in adenylate cyclase activation. Biochim Biophys Acta (1980) 0.79
Host cell range of adult T-cell leukemia virus. I. Viral infectivity and binding to various cells as detected by flow cytometry. Int J Cancer (1985) 0.79
Infection of human epithelial cells by Epstein-Barr virus (EBV). II. Biochemical characterization of EBV-determined proteins synthesized in epithelial cells. Virus Res (1985) 0.79
Human erythrocytes bearing electroinserted CD4 neutralize infection in vitro by primary isolates of human immunodeficiency virus type 1. Blood (1996) 0.79
In-vitro infection of chronic lymphocytic leukemia cells by Epstein-Barr virus (EBV). Leuk Res (1986) 0.78
Determination of the internal volume of reconstituted sendai virus envelopes by quenching of calcein fluorescence. Biosci Rep (1984) 0.78
Inhibition of membrane fusion by suppression of lateral movement of membrane proteins. Biochim Biophys Acta (1978) 0.78
False-positive enzyme-linked immunosorbent assay reactions for antibody to human immunodeficiency virus in a population of midwestern patients with congenital bleeding disorders. Transfusion (1987) 0.78
Reconstitution of the erythrocyte anion transport system: in vitro and in vivo approaches. Ann N Y Acad Sci (1980) 0.78
HIV type 1 infection of human cortical neuronal cells: enhancement by select neuronal growth factors. AIDS Res Hum Retroviruses (1994) 0.78
Lymphocyte abnormalities in preleukemia--I. Decreased NK activity, anomalous immunoregulatory cell subsets and deficient EBV receptors. Leuk Res (1983) 0.78
Synthesis of full-length viral DNA in CD4-positive membrane vesicles exposed to HIV-1. A model for studies of early stages of the hiv-1 life cycle. J Biol Chem (1996) 0.77
Human immunodeficiency virus type 1 infection requires reverse transcription of nascent viral RNA. DNA Cell Biol (1993) 0.77
Epstein-Barr virus (EBV) receptor implantation onto human B lymphocytes changes immunoglobulin secretion patterns induced by EBV infection. Eur J Immunol (1982) 0.77
Transfection of lymphoblastoid cells using DNA-loaded reconstituted Sendai virus envelopes: expression of transfected DNA and selection of transfected cells. Somat Cell Mol Genet (1986) 0.77
CD4 confers susceptibility to human immunodeficiency virus type 1 infection in a rat fibroblast cell line. AIDS Res Hum Retroviruses (1996) 0.77
Markers of human immunodeficiency virus infection in pediatric bronchoalveolar lavage samples. Ann Clin Lab Sci (1992) 0.76
Effects of differentiation inducing chemicals on in vivo malignancy and NK susceptibility of metastatic lymphoma cells. Cancer Detect Prev (1988) 0.76